BENEFIT Extension Study

Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00544037

Enrollment

283

Registered

2007-10-16

Start date

2007-09-30

Completion date

2011-01-31

Last updated

2012-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.

Interventions

DRUGInterferon beta-1b (Betaseron, BAY86-5046)

Standard Therapy for Multiple Sclerosis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

23 Years to 50 Years

Healthy volunteers

Inclusion criteria

* All patients randomized and treated at least once in study 304747

Exclusion criteria

* Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study

Design outcomes

Primary

Measure	Time frame
To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study	End of Study

Countries

Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Norway, Poland, Slovenia, Spain, Sweden, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026